{"brief_title": "Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria", "brief_summary": "OBJECTIVES: I. Determine the long-term efficacy and safety of L-cysteine in the prevention photosensitivity in patients with erythropoietic protoporphyria.", "detailed_description": "PROTOCOL OUTLINE: This is a phase III study, lasting 3 years; 1996-1999. Patients are administered L-cysteine orally twice daily, 2 capsules with breakfast and 2 with lunch. Patients fill in questionnaires and diary sheets about their reaction to sunlight exposure, and have blood tested 3 times a year. Completion date provided represents the completion date of the grant per OOPD records", "condition": ["Erythropoietic Protoporphyria"], "intervention_type": ["Drug"], "intervention_name": ["cysteine hydrochloride"], "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Erythropoietic protoporphyria RBC protoporphyrin greater than 50 micrograms/100 dL --Prior/Concurrent Therapy-- At least 3 months since prior betacarotene or L-cysteine No concurrent betacarotene --Patient Characteristics-- - Fertile female patients must use effective contraception for duration of trial and for 3 weeks thereafter - Not pregnant or nursing", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "keyword": "rare disease", "mesh_term": ["Protoporphyria, Erythropoietic"], "id": "NCT00004940"}